Neurocrine Biosciences Inc - Asset Resilience Ratio
Neurocrine Biosciences Inc (NBIX) has an Asset Resilience Ratio of 16.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Neurocrine Biosciences Inc (NBIX) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Neurocrine Biosciences Inc's Asset Resilience Ratio has changed over time. See how leveraged is Neurocrine Biosciences Inc's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Neurocrine Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Neurocrine Biosciences Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $767.40 Million | 16.57% |
| Total Liquid Assets | $767.40 Million | 16.57% |
Asset Resilience Insights
- Good Liquidity Position: Neurocrine Biosciences Inc maintains a healthy 16.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Neurocrine Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Neurocrine Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Neurocrine Biosciences Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Neurocrine Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.57% | $767.40 Million | $4.63 Billion | -6.10pp |
| 2024-12-31 | 22.67% | $843.10 Million | $3.72 Billion | -1.33pp |
| 2023-12-31 | 24.01% | $780.50 Million | $3.25 Billion | -6.66pp |
| 2022-12-31 | 30.67% | $726.40 Million | $2.37 Billion | +12.79pp |
| 2021-12-31 | 17.88% | $370.50 Million | $2.07 Billion | -17.51pp |
| 2020-12-31 | 35.39% | $613.90 Million | $1.73 Billion | -7.36pp |
| 2019-12-31 | 42.74% | $558.25 Million | $1.31 Billion | -8.53pp |
| 2018-12-31 | 51.27% | $509.20 Million | $993.15 Million | +19.32pp |
| 2017-12-31 | 31.95% | $261.22 Million | $817.59 Million | -29.43pp |
| 2016-12-31 | 61.38% | $224.08 Million | $365.09 Million | -2.86pp |
| 2015-12-31 | 64.24% | $305.00 Million | $474.79 Million | -2.75pp |
| 2014-12-31 | 66.98% | $162.79 Million | $243.03 Million | +1.72pp |
| 2013-12-31 | 65.27% | $100.95 Million | $154.68 Million | +9.52pp |
| 2012-12-31 | 55.75% | $109.26 Million | $195.98 Million | -1.34pp |
| 2011-12-31 | 57.09% | $79.00 Million | $138.37 Million | +6.67pp |
| 2010-12-31 | 50.42% | $72.81 Million | $144.42 Million | +27.63pp |
| 2009-12-31 | 22.78% | $16.14 Million | $70.82 Million | +12.62pp |
| 2008-12-31 | 10.16% | $12.01 Million | $118.18 Million | -18.66pp |
| 2007-12-31 | 28.82% | $79.72 Million | $276.65 Million | +2.74pp |
| 2006-12-31 | 26.08% | $101.62 Million | $389.68 Million | -20.10pp |
| 2005-12-31 | 46.18% | $223.12 Million | $483.12 Million | -0.06pp |
| 2004-12-31 | 46.24% | $240.10 Million | $519.22 Million | -16.34pp |
| 2003-12-31 | 62.58% | $347.31 Million | $554.96 Million | -12.60pp |
| 2002-12-31 | 75.18% | $200.40 Million | $266.54 Million | +30.12pp |
| 2001-12-31 | 45.07% | $156.09 Million | $346.35 Million | -32.15pp |
| 2000-12-31 | 77.22% | $143.59 Million | $185.96 Million | +13.30pp |
| 1999-12-31 | 63.92% | $69.80 Million | $109.20 Million | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more